Towards Innovation: Bringing the Healthcare and Life Science World Together
Technology plays an essential role in accelerating the distribution of the vaccine and evaluating, using global real-world data, how long the immunity lasts after vaccination to assess reinfection risks and determine when revaccination is necessary. The below section highlights on “How Innovation and Technologies are resulting as the Game Changer”
Emanation of synthetic biology:
Synthetic biology would predominate in coming years. It offers innovative approaches for engineering new biological systems or re-designing existing ones for useful purposes. It has been described as a disruptive technology at the heart of the so-called bioeconomy, capable of delivering new solutions to global healthcare, agriculture, manufacturing, and environmental challenge.
Promoting collaborations between academia and industry:
Collaboration is the key to successful to launch of drug products. There is need for initiatives to ensure effective industry-academia alliance
Development of personalized medicine through gene editing and biomaterial-based drug delivery systems:
Developing personalized medicine via gene editing (e.g., CRISPR) or biomaterial-based drug delivery systems are going to be trends in 2021
- Innovative technologies to ameliorate/revamp scientific research
- Increasing opportunities in adoption of automation platforms across pharmaceutical, medical device, and other life sciences businesses as it helps to enhance communications and processes to make supply chains more agile.
- Robotic process automation (RPA), AI, and deep learning are among the emerging technologies that can drive fast-tracking early drug screens like image-based phenotypic profiling based on cell painting.
- Expanding significantly is the proteomics segment where analysis can provide a complete depiction of functional and structural information of the cell and its response mechanisms to drugs and other foreign factors.
The key points of discussion would be around:
- Future-proof the foundation through modern platforms, modular architecture, and collaborations
- How do we position Synthetic biology to meet the challenges of 2021 with respect to the risks and advantages?
- Leveraging the industry academia collaboration around vaccine/mAbs research.
- Development of personalized medicine through gene editing and biomaterial-based drug delivery systems
- Innovative technologies to ameliorate/revamp scientific research
- Logical thinking and design-based solutions to address medical challenges, rather than relying on serendipity or brute force processes
- Vaccine development and innovating technologies
Speakers
Dr. Himanshu Gadgil
Director & CSO
Director & CSO
Dr. Sanjay Singh
Chief Executive Officer
Gennova Biopharmaceuticals
Dr. Swapan Jana
Director of R&D and Manufacturig
Serum Institute
Vishwanth Swarup
Chief Operating Officer
Bharat Serums and Vaccines
Mr. Sudarshan Jain
Secretary General
Indian Pharmaceutical Alliance (IPA) Senior Advisor, APAX Partners
Moderator
Agenda
|
4:30 – 4:35 |
Opening by ET Edge |
|
4:35 – 5.25 |
Round Table Discussion: Active Intelligence: Accelerating informed decisions Active Intelligence has raised the bar for technology, giving traditional methods a run for their money. With real-time and analytics-ready data, it has sped up business processes and is assisting them in making rapid and informed decisions. In this session we will discuss how this technology is rapidly evolving and will touch upon the following topics:
|
|
5.25 – 5:30 |
Closing Remarks by ET Edge |